Zenotech Lab.

When is the next results date for Zenotech Lab.?

No Upcoming Board Meetings

Has Zenotech Lab. declared dividend?

No Dividend History Available

Who are the peers of the Zenotech Lab.?

Zenotech Lab.'s peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, Oxygenta Pharma, Fredun Pharma, Trident Lifeline, and Gennex Lab. While Zenotech Lab. has average management risk and below average growth, its 1-year return is 7.64%, higher than Gennex Lab.'s but lower than Oxygenta Pharma's 169.57%.

Peers: The peers of Zenotech Lab. are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Oxygenta Pharma, Fredun Pharma, Trident Lifeline, and Gennex Lab.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, and Dr Reddy's Labs, while Average management risk is found at Zenotech Lab., Fredun Pharma, and Trident Lifeline. Below Average management risk is noted for Gennex Lab. Growth is Excellent for Sun Pharma.Inds., Cipla, Dr Reddy's Labs, and Trident Lifeline, while Below Average growth is seen at Zenotech Lab. and Torrent Pharma. Good growth is reported for Fredun Pharma and Gennex Lab., while Oxygenta Pharma does not qualify. Capital Structure is Excellent for Sun Pharma.Inds., Divi's Lab., Cipla, and Dr Reddy's Labs, Good for Torrent Pharma and Zenotech Lab., Average for Fredun Pharma, and Below Average for Gennex Lab.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Oxygenta Pharma at 169.57%, while Gennex Lab. has the lowest at -22.86%. Zenotech Lab.'s 1-year return of 7.64% is higher than Gennex Lab.'s but lower than Oxygenta Pharma's. Additionally, the six-month return is negative for Zenotech Lab., Gennex Lab., and Fredun Pharma.

Is Zenotech Lab. overvalued or undervalued?

Zenotech Lab. is currently considered very expensive and overvalued due to high valuation metrics and poor stock performance, making it a less compelling investment at its current price.

As of 13 August 2021, the valuation grade for Zenotech Lab. has moved from risky to very expensive. The company is currently overvalued based on its high valuation metrics, including a PE ratio of 86.06, an EV to EBIT ratio of 49.55, and an EV to EBITDA ratio of 25.21. These figures significantly exceed those of its peers, such as Sun Pharma with a PE of 35.25 and Divi's Lab at 79.33, indicating that Zenotech Lab. is trading at a premium compared to the industry.<BR><BR>In comparison to the broader market, Zenotech Lab.'s stock has underperformed year-to-date with a return of -11.95% against the Sensex's 5.63%. This trend reinforces the conclusion that the stock is overvalued, as investors may be paying a high price for earnings that do not justify such a valuation. Overall, the combination of elevated ratios and poor relative performance suggests that Zenotech Lab. is not a compelling investment at its current price.

What is the technical trend for Zenotech Lab.?

As of May 12, 2025, Zenotech Lab's technical trend is mildly bearish, with mixed signals from MACD, Bollinger Bands, and moving averages across different time frames.

As of 12 May 2025, the technical trend for Zenotech Lab has changed from bearish to mildly bearish. The weekly MACD indicates a mildly bullish stance, while the monthly MACD is mildly bearish, suggesting mixed signals across time frames. The Bollinger Bands show a mildly bullish trend on the weekly chart but are bearish on the monthly, further contributing to the overall mildly bearish outlook. Daily moving averages are also mildly bearish, reinforcing the current trend. The KST is mildly bullish on the weekly but mildly bearish on the monthly, indicating some short-term strength that is not reflected in the longer term. Overall, the current technical stance is mildly bearish, with key indicators showing mixed signals across different time frames.

Who are in the management team of Zenotech Lab.?

As of March 2023, the management team of Zenotech Lab includes Kavita Shah, Jignesh Anantray Goradia, Azadar Hussain Khan, Chintan Jitendra Shah, Abdul Gafoor Mohammad, Jagruti Prashant Sheth, and Rakeshchandra Jagdishprasad Sinha, consisting of independent and non-executive directors along with a compliance officer.

As of March 2023, the management team of Zenotech Lab includes the following individuals:<BR><BR>1. Kavita Shah - Independent Director<BR>2. Jignesh Anantray Goradia - Non Executive Director<BR>3. Azadar Hussain Khan - Non Executive Director<BR>4. Chintan Jitendra Shah - Independent Director<BR>5. Abdul Gafoor Mohammad - Company Secretary & Compliance Officer<BR>6. Jagruti Prashant Sheth - Independent Director<BR>7. Rakeshchandra Jagdishprasad Sinha - Non Executive Director<BR><BR>This team comprises a mix of independent and non-executive directors, along with a compliance officer.

What does Zenotech Lab. do?

Zenotech Laboratories Ltd is a micro-cap pharmaceutical company specializing in generic injectables, established in 1989. As of March 2025, it reported net sales of 111 Cr and a net profit of 12 Cr, with a market cap of INR 378 Cr.

Overview: <BR>Zenotech Laboratories Ltd is a pharmaceutical specialty generic injectables company operating in the Pharmaceuticals & Biotechnology industry, categorized as a Micro Cap.<BR><BR>History: <BR>Zenotech Laboratories Limited was established in June 1989 and changed its name from Sunline Technologies Limited on August 9, 2004. The most recent quarterly results reported net sales and net profit for the period ending March 2025.<BR><BR>Financial Snapshot: <BR>Net Sales: 111 Cr (Quarterly Results - Mar 2025) <BR>Net Profit: 12 Cr (Quarterly Results - Mar 2025) <BR>Market Cap: INR 378 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 83.00 <BR>Industry P/E: 37 <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.28 <BR>Return on Equity: 4.65% <BR>Price to Book: 3.85 <BR><BR>Contact Details: <BR>Address: S No 250-252 Turkapally Village, Shameerpet Mandal RR District Hyderabad Telangana : 500078 <BR>Tel: 91-40-23480430/0435 <BR>Email: abdul.gafoor@zenotech.co.in <BR>Website: http://www.zenotechlab.com

Who are the top shareholders of the Zenotech Lab.?

The top shareholders of Zenotech Lab are Sun Pharmaceutical Industries Limited with 68.84%, followed by Padmasree Chigurupati at 5.26%, and individual investors holding 22.78%. There are no mutual funds or foreign institutional investors currently involved.

The top shareholders of Zenotech Lab include Sun Pharmaceutical Industries Limited, which holds a significant majority stake of 68.84%. The highest public shareholder is Padmasree Chigurupati, with a holding of 5.26%. Additionally, individual investors collectively hold 22.78% of the company's shares. There are currently no mutual funds or foreign institutional investors (FIIs) holding shares in Zenotech Lab.

How big is Zenotech Lab.?

As of 24th July, Zenotech Laboratories Ltd has a market capitalization of 391.00 Cr and reported net sales of 38.97 Cr and a net profit of 5.56 Cr in the latest four quarters. Specific values for Shareholder's Funds and Total Assets are not available.

As of 24th July, Zenotech Laboratories Ltd has a market capitalization of 391.00 Cr, classified as a Micro Cap.<BR><BR>In the latest four quarters, Zenotech Laboratories Ltd reported net sales of 38.97 Cr and a net profit of 5.56 Cr.<BR><BR>The reporting period for the balance sheet is the latest annual period, but specific values for Shareholder's Funds and Total Assets are not available.

How has been the historical performance of Zenotech Lab.?

Zenotech Lab has experienced declining net sales and increasing losses from 2008 to 2010, with net sales dropping from 8.24 Cr to 6.57 Cr. However, there are signs of improvement in cash management, as cash and cash equivalents rose significantly during the same period.

Answer:<BR>The historical performance of Zenotech Lab shows a trend of declining net sales and increasing losses over the years reported.<BR><BR>Breakdown:<BR>Zenotech Lab's net sales decreased from 8.24 Cr in March 2008 to 6.57 Cr in March 2010, with a slight increase from 6.02 Cr in March 2009. The total operating income mirrored this trend, remaining at 6.57 Cr in March 2010, down from 8.24 Cr in March 2008. The total expenditure, excluding depreciation, also declined from 18.12 Cr in March 2008 to 16.01 Cr in March 2010. However, the operating profit (PBDIT) remained negative, improving slightly from -9.88 Cr in March 2008 to -7.33 Cr in March 2010. The profit before tax showed a similar pattern, with losses narrowing from -13.54 Cr in March 2008 to -12.54 Cr in March 2010. The profit after tax also reflected this negative trend, with losses of -15.89 Cr in March 2008, -17.56 Cr in March 2009, and -12.53 Cr in March 2010. The earnings per share improved from -4.39 in March 2008 to -3.45 in March 2010. Cash flow from operating activities remained negative, although it improved from -15.54 Cr in March 2009 to -9.85 Cr in March 2010. The closing cash and cash equivalents increased significantly from 0.60 Cr in March 2008 to 12.33 Cr in March 2010, indicating a positive cash flow from investing activities. Overall, Zenotech Lab has faced challenges with profitability, but there are signs of improvement in cash management.

Are Zenotech Laboratories Ltd latest results good or bad?

Zenotech Laboratories Ltd's latest results are largely negative, showing a net loss of -₹0.84 crore despite an 18.40% increase in revenue. The significant decline in profitability and operating margins raises concerns about the company's financial health.

Zenotech Laboratories Ltd's latest results present a mixed picture, leaning towards the negative due to significant profitability challenges. In Q2 FY26, the company reported a net profit of -₹0.84 crore, which is a drastic decline of 184.85% quarter-on-quarter and 162.22% year-on-year. This loss was primarily driven by an extraordinary tax charge that exceeded the profit before tax by a substantial margin, leading to a net loss despite an increase in revenue.<BR><BR>On the positive side, the revenue for the quarter reached ₹10.23 crore, marking an 18.40% increase from the previous quarter and a 16.91% increase year-on-year. This growth in revenue is encouraging, but it is overshadowed by the sharp decline in operating margins, which fell to 22.29% from 28.47% in the previous quarter, indicating rising cost pressures.<BR><BR>Additionally, the return on equity (ROE) has plummeted to 2.81%, significantly below the historical average of 16.36%, reflecting the company's struggles to generate returns for shareholders. The overall financial performance suggests that while there is revenue growth, the underlying operational efficiency and profitability are concerning.<BR><BR>In summary, while Zenotech Laboratories has shown revenue growth, the substantial net loss and deteriorating margins indicate that the latest results are more negative than positive, raising questions about the company's financial health and operational effectiveness.

Should I buy, sell or hold Zenotech Laboratories Ltd?

Which are the latest news on Zenotech Lab.?

Why is Zenotech Laboratories Ltd falling/rising?

As of 03-Feb, Zenotech Laboratories Ltd's stock price is at 44.81, showing a 2.14% increase after two days of decline. However, it remains below moving averages, close to its 52-week low, and has significantly underperformed over the past year, indicating ongoing challenges in the market.

As of 03-Feb, Zenotech Laboratories Ltd's stock price is rising, currently at 44.81, with a change of 0.94 (2.14%) upward. This increase comes after a trend reversal, as the stock has gained after two consecutive days of decline. However, it is important to note that despite this rise, the stock has underperformed its sector by 0.65% today and is still trading below its moving averages across various time frames, indicating a generally weaker performance compared to historical averages.<BR><BR>Additionally, the stock is close to its 52-week low, being only 4.02% away from the low of Rs 43.01. The performance over the past month shows a decline of 5.40%, while year-to-date, it has decreased by 2.99%. Over the past year, the stock has significantly underperformed, with a drop of 29.87%, contrasting sharply with the Sensex, which has gained 8.49% in the same period. <BR><BR>Furthermore, there has been a notable decline in investor participation, with delivery volume falling by 86.81% against the 5-day average, which may indicate reduced interest or confidence among investors. Despite the current rise, these factors suggest that the stock is still facing significant challenges in the broader market context.